GlassScriptPhysician profile
Thomas Luke Heil
NPI 1326001256
$5,069.27
in general payments reported to CMS, 2019-2025
19 companies · $1,365 in 2025
The $1,365 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,971 · 2020: $317 · 2021: $139 · 2022: $183 · 2023: $537 · 2024: $556 · 2025: $1,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,062 · Travel and Lodging: $383 · Education: $13.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,062.40 |
| Travel and Lodging | $382.99 |
| Education | $13.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,841.39 | 2019-2025 | Wavewriter Alpha Prime 16, General - Therapies |
| Medtronic, INC. | $615.89 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Medtronic USA, INC. | $457.11 | 2019-2020 | |
| Abbott Laboratories | $315.59 | 2019-2025 | Eterna |
| Spr Therapeutics, INC | $151.72 | 2019 | |
| Mml US, INC. | $130.26 | 2024 | Reactiv8 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.70 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $80.67 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $76.92 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $42.68 | 2019 | |
| Nalu Medical, INC. | $40.61 | 2023-2024 | Nalu Neurostimulation System |
| Pfizer INC. | $35.90 | 2019-2020 | |
| Amgen INC. | $28.28 | 2019-2020 | |
| Curonix LLC | $27.97 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Assertio Therapeutics, INC. | $26.97 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $25.48 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $23.13 | 2019-2020 | |
| Stimwave Technologies Incorporated | $21.19 | 2019 | |
| Lilly USA, LLC | $14.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Heil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.